Chen Peng, Xi Qiulei, Wang Qiang, Wei Pei
Department of Gastroenterology, Zaozhuang Mining Group Central Hospital, Qilianshan Road, Zaozhuang, 277800, China,
Med Oncol. 2014 Oct;31(10):235. doi: 10.1007/s12032-014-0235-x. Epub 2014 Sep 13.
Dysregulation of microRNA-100 (miR-100) has been shown to be involved in cancer tumorigenesis and progression of several cancer types. However, its expression patterns in tumors are controversial. The aim of this study was to investigate the expression and clinical significance of miR-100 in colorectal cancer (CRC). Quantitative real-time PCR was used to analyze the expression of miR-100 in 138 pairs of human CRC and adjacent normal tissues. The prognostic values of miR-100 in CRC were also analyzed. The results showed that the miR-100 expression was significantly downregulated in CRC tissues when compared to adjacent normal tissues (P<0.001). Also, low miR-100 expression was observed to be significantly correlated with larger tumor size (P=0.023), higher incidence of lymph node metastasis (P=0.009), and advanced TNM stage (P=0.016). More importantly, Kaplan-Meier analysis showed that CRC patients with low miR-100 expression tended to have shorter overall survival. In multivariate analysis stratified for known prognostic variables, low miR-100 expression was identified as an independent prognostic factor for overall survival. In conclusion, our data indicated for the first time that the downregulation of miR-100 was associated with advanced clinical features and poor prognosis of CRC patients, suggesting that miR-100 downregulation may serve as an unfavorable prognostic biomarker in CRC.
微小RNA-100(miR-100)的失调已被证明与多种癌症类型的肿瘤发生和进展有关。然而,其在肿瘤中的表达模式存在争议。本研究的目的是探讨miR-100在结直肠癌(CRC)中的表达及临床意义。采用定量实时PCR分析138对人CRC组织及癌旁正常组织中miR-100的表达,并分析miR-100在CRC中的预后价值。结果显示,与癌旁正常组织相比,CRC组织中miR-100表达显著下调(P<0.001)。此外,观察到低miR-100表达与更大的肿瘤大小(P=0.023)、更高的淋巴结转移发生率(P=0.009)和晚期TNM分期(P=0.016)显著相关。更重要的是,Kaplan-Meier分析显示,miR-100表达低的CRC患者总生存期往往较短。在对已知预后变量进行分层的多变量分析中,低miR-100表达被确定为总生存期的独立预后因素。总之,我们的数据首次表明miR-100的下调与CRC患者的晚期临床特征和不良预后相关,提示miR-100下调可能作为CRC中一个不良的预后生物标志物。